报价延迟最少15分钟:2026/09/23 20:03 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
19.97 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.85/--
|
|
企业价值
1.38B
|
| 资产负债 |
|
每股账面净值
-4.16
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches. |
